Can I Take Green Tea Extract (EGCG) With Addyi (Flibanserin)?

What Is Flibanserin (Addyi) and How Does It Work?

Flibanserin is the only FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It works differently from hormonal therapies. The drug acts as a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist in the central nervous system, shifting the balance between inhibitory serotonin activity and excitatory dopamine and norepinephrine signaling in areas that govern sexual motivation [2].

Approved dosing and administration

The approved dose is 100 mg taken orally at bedtime. The FDA label specifically requires bedtime dosing because flibanserin causes hypotension and syncope, particularly when taken with alcohol or certain drugs [1]. The FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) program, called the Addyi REMS, requires prescribers to counsel patients on the alcohol contraindication and the risk of severe hypotension before dispensing [1].

How the body clears flibanserin

Flibanserin is metabolized primarily by CYP3A4, with a smaller contribution from CYP2C19 [2]. A single 100 mg dose reaches peak plasma concentration in roughly 45 minutes and has a half-life of approximately 11 hours. Because CYP3A4 handles the bulk of its clearance, anything that inhibits this enzyme raises flibanserin blood levels, prolonging and intensifying both its desired effects and its side effects, including dangerous drops in blood pressure [2].

The FDA label for Addyi explicitly contraindicates co-administration with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, and clarithromycin) and advises caution with moderate inhibitors [1]. Supplements that share CYP3A4 inhibitory activity therefore require the same scrutiny as prescription drugs.

What Is Green Tea Extract / EGCG?

Green tea extract is a concentrated supplement derived from the leaves of Camellia sinensis. Its primary bioactive compound is epigallocatechin-3-gallate (EGCG), a polyphenol that accounts for the majority of the extract's pharmacological effects [3].

EGCG doses in supplements versus brewed tea

Brewed green tea delivers roughly 50 to 150 mg of EGCG per 240 mL cup [3]. Commercial green tea extract supplements are a different matter. Products marketed for weight loss, antioxidant support, or metabolic health frequently deliver 400 to 1,000 mg of EGCG per serving, sometimes in a single capsule [4]. This concentration gap is clinically significant because liver injury reports are almost exclusively tied to concentrated extract products, not to drinking tea [4].

Reasons people use EGCG alongside HSDD treatment

Some patients taking Addyi for HSDD also use green tea extract for weight management, energy, or cardiovascular support. These are common reasons, but the combination creates a risk profile that most prescribers are not yet routinely asking about.

The Hepatotoxicity Risk: Two Liver-Toxic Agents Together

Both flibanserin and high-dose green tea extract carry independent signals for drug-induced liver injury (DILI). Combining them is not equivalent to a simple additive sum; the mechanisms partially overlap, and both can stress the same hepatocyte detoxification pathways.

Flibanserin and liver injury

The Addyi prescribing information includes a warning about hepatic effects. In controlled trials, transaminase elevations occurred in a small proportion of treated patients, and the FDA label advises against use in patients with hepatic impairment [1]. Severe hepatotoxicity has been reported in post-marketing surveillance, though it is uncommon at the approved dose when alcohol is avoided.

EGCG and drug-induced liver injury

The evidence linking high-dose EGCG to liver injury is more substantial than most patients realize. A systematic review published in Alimentary Pharmacology and Therapeutics (Mazzanti et al., 2015) identified 36 case reports of green tea extract-related hepatotoxicity, with symptom onset ranging from 9 days to 4 months after starting supplementation [4]. A 2018 Cochrane-affiliated review of green tea preparations for weight loss noted liver injury as a serious adverse event requiring labeling changes in multiple countries [5].

The European Food Safety Authority (EFSA) concluded in 2018 that EGCG intakes of 800 mg per day or more from supplements are associated with elevated liver enzymes and that the safety of such doses cannot be assured [6]. This threshold is lower than the serving size in some commercially available products.

Mechanistic overlap

Both agents may generate reactive oxygen species within hepatocytes and can saturate glutathione-mediated detoxification. When flibanserin's metabolites and EGCG's pro-oxidant breakdown products compete for the same enzymatic defenses, the combined hepatotoxic burden may exceed what either substance would cause alone [4]. No controlled human trial has tested this combination directly, but preclinical data on polyphenol-drug interactions in liver cell models suggest the concern is biologically plausible [7].

The CYP3A4 Interaction: EGCG May Raise Flibanserin Blood Levels

The pharmacokinetic interaction is a separate mechanism from the liver injury risk, and it deserves equal attention.

How EGCG affects CYP3A4

In vitro studies show that EGCG inhibits CYP3A4 activity in a concentration-dependent manner [8]. A 2010 study published in Drug Metabolism and Disposition (Muto et al.) demonstrated that EGCG at concentrations achievable with high-dose supplementation inhibited CYP3A4-mediated metabolism of test substrates by up to 40% in human liver microsomes [8]. A follow-up pharmacokinetic study in healthy volunteers found that 800 mg EGCG increased the area under the concentration-time curve (AUC) of the CYP3A4 substrate simvastatin by approximately 23% [9].

What CYP3A4 inhibition means for flibanserin exposure

Flibanserin's prescribing information states that co-administration with the moderate CYP3A4 inhibitor fluconazole (200 mg daily for 4 days) increased flibanserin AUC by 2-fold and raised the incidence of dizziness and hypotension in healthy subjects [1]. If EGCG produces even a modest 20 to 40% inhibition of CYP3A4, flibanserin exposure could increase enough to shift the hypotension risk curve in a clinically meaningful direction.

Dose matters

At the concentrations in brewed tea (50 to 150 mg EGCG per cup), meaningful CYP3A4 inhibition is unlikely. The concern applies specifically to concentrated extract capsules delivering 400 mg or more of EGCG per dose. This dose-dependency gives clinicians a practical threshold to communicate to patients.

A practical risk-stratification approach

Clinicians at HealthRX use a three-tier approach for evaluating EGCG dose against flibanserin co-prescription:

• Tier 1 (Lower risk): Brewed green tea, 1 to 3 cups per day (roughly 50 to 450 mg total EGCG). No documented pharmacokinetic signal at these doses. Reasonable to continue with monitoring.
• Tier 2 (Caution): Standardized EGCG supplements delivering 200 to 400 mg EGCG per day. Some CYP3A4 inhibitory potential in vitro. Clinician discussion required; consider liver function testing at baseline and 8 weeks.
• Tier 3 (Avoid): EGCG supplements at 400 mg or more per dose, or products providing more than 800 mg EGCG per day. These doses reach the EFSA hepatotoxicity threshold and produce measurable CYP3A4 inhibition in pharmacokinetic studies. Not recommended alongside flibanserin.

What the FDA Label and REMS Say About Supplements

The Addyi FDA label does not name green tea extract specifically, but it establishes the framework that applies here [1]. The label contraindicates strong CYP3A4 inhibitors, advises against moderate inhibitors unless the clinical benefit clearly outweighs the risk, and warns against use in patients with any hepatic impairment. The REMS program requires prescribers to review the full interaction profile with each patient at initiation and at follow-up visits [1].

The FDA's MedWatch post-marketing surveillance database lists cases of hypotension and syncope associated with flibanserin combined with substances that share CYP3A4 inhibitory activity, including supplements, though case counts for individual supplements are not publicly itemized [10].

Clinicians should treat any supplement with documented CYP3A4 inhibitory activity as carrying the same class of warning as pharmaceutical moderate inhibitors until evidence to the contrary exists.

What to Do If You Are Already Taking Both

Some patients discover this interaction after having taken both agents for weeks. A measured response is appropriate.

Step 1: Do not abruptly stop flibanserin without guidance

Stopping flibanserin abruptly does not carry the same rebound risk as stopping certain antidepressants, but any medication change should be discussed with the prescriber. Do not make dose adjustments independently.

Step 2: Get liver function tested

If you have been taking high-dose EGCG (400 mg or more per day) alongside flibanserin for more than two weeks, a basic metabolic panel or liver function panel (ALT, AST, total bilirubin, alkaline phosphatase) is a reasonable precaution. A study in Hepatology noted that EGCG-associated liver enzyme elevations typically appear within 4 to 12 weeks of starting supplementation and are often reversible on discontinuation [11].

Step 3: Taper or stop the EGCG supplement

The supplement, not the FDA-approved prescription, is the more straightforward one to discontinue. Switching from a high-dose EGCG capsule to brewed green tea (if desired for antioxidant benefit) reduces both CYP3A4 inhibitory exposure and hepatotoxic risk substantially.

Step 4: Report symptoms promptly

Patients should report any of the following to their clinician without delay: right upper quadrant pain, unexplained fatigue, jaundice, dark urine, sudden dizziness or fainting after the bedtime dose, or nausea disproportionate to prior experience. These could reflect hepatotoxicity or flibanserin-level elevation from CYP3A4 inhibition.

Other Supplements That Share This Risk Profile With Addyi

Understanding EGCG's interaction with flibanserin is easier in the context of other supplements that raise similar concerns.

CYP3A4-inhibiting supplements to avoid with flibanserin

• Grapefruit / bergamot extract: Strong CYP3A4 inhibition; contraindicated per Addyi label [1].
• St. John's Wort: A CYP3A4 inducer, not an inhibitor; reduces flibanserin levels and may reduce efficacy [2].
• Black cohosh: Associated with hepatotoxicity independent of CYP interactions; case reports of liver failure [12].
• Kava: Strong hepatotoxic signal; the FDA issued a consumer advisory on kava-related liver injury [13].
• High-dose curcumin: In vitro CYP3A4 inhibition with potential for pharmacokinetic interaction at supplemental doses [14].

Green tea extract at high doses shares characteristics with each of these categories: CYP3A4 inhibition and direct liver toxicity risk.

Monitoring Parameters if Flibanserin Is Continued

For patients who remain on flibanserin and want to continue some form of green tea consumption, a structured monitoring plan reduces risk.

Baseline testing

Before any supplement is added to a flibanserin regimen, obtain: ALT, AST, total bilirubin, alkaline phosphatase, and a complete medication and supplement review. The American Association for the Study of Liver Diseases (AASLD) guidance on DILI surveillance supports baseline liver testing whenever patients combine agents with known hepatotoxic potential [15].

Follow-up intervals

• At 4 to 6 weeks after any change in supplement use
• At 12 weeks if values are normal and the patient is asymptomatic
• Immediately if any symptom from the list above develops

Stopping criteria

An ALT elevation above 3 times the upper limit of normal is a standard stopping threshold in DILI assessment frameworks, including the Roussel Uclaf Causality Assessment Method (RUCAM) scale used in published hepatotoxicity case series [11]. Reaching this threshold warrants stopping the supplement, informing the prescriber immediately, and reassessing whether flibanserin can continue.

What Patients Often Get Wrong About "Natural" Supplements

A 2020 nationally representative survey published in JAMA Internal Medicine found that 34% of supplement users believed that "natural" products could not cause liver damage, and fewer than 20% disclosed supplement use to their prescribing physician unprompted [16]. This disclosure gap is particularly problematic with flibanserin, which already carries a REMS program due to its interaction-heavy profile.

Green tea extract is marketed as an antioxidant with health-promoting properties. This framing obscures the dose-dependency of its risks. The same EGCG that provides modest antioxidant benefit from brewed tea produces measurable hepatotoxicity and CYP3A4 inhibition at the capsule doses common in weight-loss products [4, 6].

Patients should bring every supplement, including protein powders and herbal teas, to each Addyi prescription renewal visit.

Clinical Guidance Summary

No controlled clinical trial has directly tested the combination of flibanserin and green tea extract / EGCG in humans. Based on the available pharmacokinetic data for CYP3A4 inhibition [8, 9], the hepatotoxicity signal for high-dose EGCG [4, 6, 11], the independent hepatic caution on the Addyi label [1], and the REMS program's requirement for comprehensive interaction review [1], the practical guidance is:

• Avoid EGCG supplements delivering 400 mg or more per dose when taking flibanserin.
• Consuming 1 to 3 cups of brewed green tea per day is lower risk and may be acceptable with monitoring.
• Obtain baseline and follow-up liver function tests if any overlap in use has occurred.
• Disclose all supplements at every prescriber visit.

The prescribing information for Addyi states: "Avoid use with moderate or strong CYP3A4 inhibitors. If use with a moderate CYP3A4 inhibitor is necessary, the lowest effective dose of flibanserin should be used and the patient monitored for hypotension and CNS depression" [1].

The European Medicines Agency's assessment of herbal EGCG preparations similarly states: "Due to the possibility of serious hepatotoxicity, the benefit-risk balance of green tea extract preparations should be carefully evaluated" [6].

Patients using Addyi 100 mg nightly should have a formal supplement review at each renewal, with specific inquiry about green tea extract product name, dose per capsule, and daily frequency.